Free Trial

Grifols (GRFS) Competitors

Grifols logo
$9.14 +0.14 (+1.56%)
Closing price 04:00 PM Eastern
Extended Trading
$9.14 -0.01 (-0.05%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GRFS vs. TEVA, SMMT, ITCI, GMAB, RDY, ASND, VTRS, QGEN, MRNA, and BPMC

Should you be buying Grifols stock or one of its competitors? The main competitors of Grifols include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Moderna (MRNA), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry.

Grifols vs. Its Competitors

Teva Pharmaceutical Industries (NYSE:TEVA) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Teva Pharmaceutical Industries has a beta of 0.6, indicating that its stock price is 40% less volatile than the S&P 500. Comparatively, Grifols has a beta of 0.55, indicating that its stock price is 45% less volatile than the S&P 500.

Teva Pharmaceutical Industries currently has a consensus price target of $24.13, indicating a potential upside of 41.33%. Grifols has a consensus price target of $10.30, indicating a potential upside of 12.69%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, equities analysts plainly believe Teva Pharmaceutical Industries is more favorable than Grifols.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.22
Grifols
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.00

Grifols has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$16.54B1.18-$1.64B-$1.15-14.84
Grifols$7.81B0.81$169.80M$1.177.81

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Teva Pharmaceutical Industries had 17 more articles in the media than Grifols. MarketBeat recorded 18 mentions for Teva Pharmaceutical Industries and 1 mentions for Grifols. Grifols' average media sentiment score of 0.82 beat Teva Pharmaceutical Industries' score of 0.74 indicating that Grifols is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
7 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Grifols
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Grifols has a net margin of 0.00% compared to Teva Pharmaceutical Industries' net margin of -7.74%. Teva Pharmaceutical Industries' return on equity of 45.44% beat Grifols' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries-7.74% 45.44% 6.95%
Grifols N/A N/A N/A

Summary

Teva Pharmaceutical Industries beats Grifols on 12 of the 17 factors compared between the two stocks.

Get Grifols News Delivered to You Automatically

Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRFS vs. The Competition

MetricGrifolsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$6.28B$2.42B$5.49B$8.94B
Dividend YieldN/A1.79%5.38%4.13%
P/E Ratio7.818.9526.2119.90
Price / Sales0.81663.84415.20165.00
Price / Cash9.66154.3736.4957.06
Price / Book0.674.548.055.38
Net Income$169.80M$31.16M$3.15B$248.50M
7 Day Performance7.40%0.16%1.93%2.99%
1 Month Performance10.12%8.82%4.91%6.03%
1 Year Performance40.18%2.56%35.87%20.40%

Grifols Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GRFS
Grifols
4.1197 of 5 stars
$9.14
+1.6%
$10.30
+12.7%
+43.3%$6.28B$7.81B7.8126,300Analyst Downgrade
TEVA
Teva Pharmaceutical Industries
4.0707 of 5 stars
$16.96
+0.1%
$24.44
+44.1%
+2.0%$19.45B$16.54B-14.7536,830
SMMT
Summit Therapeutics
2.6135 of 5 stars
$20.39
-0.8%
$35.09
+72.1%
+160.4%$15.14B$700K-59.97110Analyst Upgrade
ITCI
Intra-Cellular Therapies
0.908 of 5 stars
$131.87
flat
$109.70
-16.8%
N/A$14.05B$680.50M-151.57560
GMAB
Genmab A/S
3.8833 of 5 stars
$20.68
-2.3%
$39.17
+89.4%
-16.5%$13.26B$3.12B11.752,682High Trading Volume
RDY
Dr. Reddy's Laboratories
2.7934 of 5 stars
$15.31
+0.5%
$16.95
+10.7%
-1.0%$12.78B$3.81B23.2027,811
ASND
Ascendis Pharma A/S
3.5535 of 5 stars
$175.78
-0.6%
$220.67
+25.5%
+28.4%$10.75B$393.54M-27.991,017Positive News
VTRS
Viatris
3.0377 of 5 stars
$8.85
-0.2%
$10.40
+17.5%
-13.3%$10.39B$14.74B-2.7932,000
QGEN
Qiagen
3.7647 of 5 stars
$46.72
-0.1%
$47.74
+2.2%
+23.2%$10.39B$2.00B117.145,765Dividend Announcement
MRNA
Moderna
4.3556 of 5 stars
$25.67
-0.9%
$46.61
+81.6%
-75.3%$9.93B$3.14B-2.945,800Trending News
Options Volume
Gap Up
BPMC
Blueprint Medicines
1.5434 of 5 stars
$128.40
+0.2%
$128.06
-0.3%
+17.5%$8.29B$508.82M-51.98640High Trading Volume

Related Companies and Tools


This page (NASDAQ:GRFS) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners